Nantahala Capital Management LLC Sells 420,000 Shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT)

Nantahala Capital Management LLC lowered its stake in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) by 10.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,580,000 shares of the medical device company’s stock after selling 420,000 shares during the quarter. Nantahala Capital Management LLC owned approximately 2.75% of Xtant Medical worth $2,255,000 as of its most recent SEC filing.

Separately, Vanguard Group Inc. increased its stake in shares of Xtant Medical by 3.2% in the first quarter. Vanguard Group Inc. now owns 1,548,312 shares of the medical device company’s stock valued at $1,812,000 after buying an additional 48,319 shares during the period. Institutional investors and hedge funds own 69.33% of the company’s stock.

Xtant Medical Stock Performance

NYSEAMERICAN XTNT opened at $0.68 on Tuesday. The firm has a market capitalization of $88.09 million, a P/E ratio of -67.60 and a beta of 0.36. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.44 and a quick ratio of 1.01. Xtant Medical Holdings, Inc. has a twelve month low of $0.51 and a twelve month high of $1.45.

Xtant Medical (NYSEAMERICAN:XTNT) last posted its quarterly earnings data on Thursday, August 8th. The medical device company reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.01). The firm had revenue of $29.94 million during the quarter. Xtant Medical had a negative net margin of 3.00% and a negative return on equity of 6.71%.

About Xtant Medical

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.